January 6, 2022 Ms. Lauren Sabella [Address] [City, State, Zip Code] Dear Lauren:Employment Agreement • March 18th, 2022 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
Contract Type FiledMarch 18th, 2022 Company IndustryThis letter agreement amends the Employment Agreement between you and Acorda Therapeutics, Inc. (the "Company") dated as of June 8, 2015 (the “Employment Agreement”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Employment Agreement.
Master CONSULTING AGREEMENTMaster Consulting Agreement • March 18th, 2022 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 18th, 2022 Company Industry JurisdictionThis Master Consulting Agreement (“Agreement”) is entered into as of January 1, 2022 (“Effective Date”) by and between Acorda Therapeutics, Inc., a Delaware corporation with offices at 420 Saw Mill River Road, Ardsley, NY 10502 (“Acorda”) and Burkhard Blank, M.D. residing at [address] (“Consultant”). Each of Acorda and Consultant are sometimes hereinafter referred to as a “Party” or collectively as the “Parties.”
FIRST AMENDMENT TO MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • March 18th, 2022 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
Contract Type FiledMarch 18th, 2022 Company IndustryTHIS FIRST AMENDMENT to the MANUFACTURING SERVICES AGREEMENT (the “First Amendment”) is made and entered into on this 28th day of October 2021 (the “First Amendment Effective Date”), by and between Acorda Therapeutics, Inc. (“Acorda”), a Delaware corporation, and Catalent Massachusetts, LLC (“Manufacturer”), a Delaware limited liability company.
RE:SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement • March 18th, 2022 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 18th, 2022 Company Industry JurisdictionThis letter (the “Agreement”) confirms that your employment with Acorda Therapeutics, Inc. (the "Company" or “Acorda”) will terminate effective the close of business, December 31, 2021 (the “Effective Date”), and you will have no further job responsibilities as an employee with the Company, its subsidiaries and affiliates. In addition, your resignation from all offices and directorships you hold with the Company, its subsidiaries and affiliates will be deemed effective as of the Effective Date. The terms of this Agreement are as follows:
SECOND AMENDMENT TO MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • March 18th, 2022 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
Contract Type FiledMarch 18th, 2022 Company IndustryTHIS SECOND AMENDMENT to the MANUFACTURING SERVICES AGREEMENT (the “Second Amendment”) is made and entered into on this 31st day of December 2021 (the “Second Amendment Effective Date”), by and between Acorda Therapeutics, Inc. (“Acorda”), a Delaware corporation, and Catalent Massachusetts, LLC (“Manufacturer”), a Delaware limited liability company.